Magnetar Financial LLC Makes New Investment in United Therapeutics Corporation $UTHR

Key Points

• Magnetar Financial LLC has acquired 7,988 shares of United Therapeutics Corporation, valued at approximately $2,462,000, marking a new position for the firm in the biotechnology company.
• Analysts have varying price targets for United Therapeutics, with UBS Group raising its target from $385 to $415, while JPMorgan Chase & Co. lowered theirs from $350 to $330.
• The company's recent quarterly earnings report showed a net margin of 40.36% but fell short of analysts' EPS estimates, posting $6.41 compared to the anticipated $6.80.

Magnetar Financial LLC acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 7,988 shares of the biotechnology company's stock, valued at approximately $2,462,000.

A number of other institutional investors have also added to or reduced their stakes in UTHR. WPG Advisers LLC bought a new position in shares of United Therapeutics during the first quarter valued at $60,000. Trexquant Investment LP purchased a new position in United Therapeutics in the first quarter worth about $2,749,000. OMERS ADMINISTRATION Corp boosted its position in United Therapeutics by 22.4% in the first quarter. OMERS ADMINISTRATION Corp now owns 8,944 shares of the biotechnology company's stock worth $2,757,000 after purchasing an additional 1,634 shares during the last quarter. CreativeOne Wealth LLC boosted its position in United Therapeutics by 22.6% in the first quarter. CreativeOne Wealth LLC now owns 764 shares of the biotechnology company's stock worth $236,000 after purchasing an additional 141 shares during the last quarter. Finally, Epoch Investment Partners Inc. lifted its position in shares of United Therapeutics by 26.4% during the 1st quarter. Epoch Investment Partners Inc. now owns 285,873 shares of the biotechnology company's stock valued at $88,126,000 after buying an additional 59,661 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

United Therapeutics Trading Up 32.8%

NASDAQ UTHR traded up $100.05 on Tuesday, reaching $404.81. 3,141,718 shares of the company were exchanged, compared to its average volume of 547,665. The business's fifty day moving average price is $299.03 and its 200 day moving average price is $304.77. The stock has a market capitalization of $18.26 billion, a P/E ratio of 15.80, a price-to-earnings-growth ratio of 4.62 and a beta of 0.62. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same period last year, the firm posted $5.85 EPS. The business's quarterly revenue was up 11.7% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 12,000 shares of the stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the transaction, the chief financial officer owned 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher Causey sold 3,000 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $423.21, for a total value of $1,269,630.00. Following the transaction, the director directly owned 4,865 shares in the company, valued at approximately $2,058,916.65. The trade was a 38.14% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 84,681 shares of company stock worth $25,807,469. Corporate insiders own 10.30% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Jefferies Financial Group lifted their price objective on United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research report on Tuesday. HC Wainwright set a $400.00 price target on United Therapeutics and gave the company a "buy" rating in a report on Thursday, July 31st. JPMorgan Chase & Co. reduced their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 8th. Bank of America raised their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a research report on Tuesday. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of United Therapeutics in a report on Thursday, August 14th. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $403.54.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.